ReviewCancer medicine2025
Dualistic Roles of High Mobility Group Box 1 in Cancer and Inflammation.
Review in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment.Frontiers in immunology · 2026Review
- Dualistic Roles of High Mobility Group Box 1 in Cancer and Inflammation.Cancer medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe High Mobility Group Box 1 (HMGB1) protein, a member of the HMG family, plays a crucial role in both cancer progression and inflammatory responses. HMGB1 can act as a damage-associated molecular pattern (DAMP) to activate immune responses and modulate inflammation. Its dualistic roles in promoting and inhibiting tumor growth, as well as its involvement in DNA repair and drug resistance, make it a key target for understanding and treating cancer and inflammatory diseases.
objectiveThis review aims to explore the dualistic roles of HMGB1 in cancer and inflammation, focusing on its pro-inflammatory and anti-inflammatory functions in the tumor microenvironment, its impact on DNA damage repair and tumor drug resistance, and its potential as a therapeutic target for cancer and inflammatory diseases.
methodsWe conducted a comprehensive review of the literature on HMGB1, analyzing its structural features, biological functions, and mechanisms of action in various pathological contexts. We also examined the impact of HMGB1 on tumor progression, immune responses, and metabolic reprogramming in cancer cells, as well as its role in inflammatory signaling pathways.
resultsHMGB1 exhibits both oncogenic and tumor-suppressive effects in cancer. It promotes tumor growth, metastasis, and immune evasion through mechanisms such as shaping the tumor microenvironment, driving metabolic reprogramming, and inducing drug resistance. Conversely, HMGB1 can enhance anti-tumor immunity by activating dendritic cells and T cells. In inflammation, HMGB1 acts as a DAMP, activating immune responses via receptors like RAGE and TLR4. Its redox state and subcellular localization determine its proinflammatory or anti-inflammatory functions. Targeting HMGB1 has shown promise in preclinical and clinical studies, with potential applications in anti-cancer and anti-inflammatory therapies.
conclusionThe dualistic roles of HMGB1 in cancer and inflammation highlight its complexity and potential as a therapeutic target. Future research should focus on elucidating the context-specific mechanisms of HMGB1, developing precision-targeted therapies to modulate its multifunctional activities, and translating these findings into clinical practice to improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.